E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/27/2017 in the Prospect News Structured Products Daily.

New Issue: Morgan Stanley sells $1.14 million 8.28% contingent income autocalls tied to stocks

By Susanna Moon

Chicago, Oct. 27 – Morgan Stanley Finance LLC priced $1.14 million of contingent income autocallable securities due Oct. 29, 2020 linked to worse performing of the common stocks of Celgene Corp. and Amgen Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes will pay a contingent quarterly coupon at an annual rate of 8.28% if each stock closes at or above the 65% downside threshold on the determination date for that quarter.

The notes will be called at par plus the contingent coupon if each stock closes at or above the initial level on any determination date after six months.

The payout at maturity will be par plus the contingent coupon unless either stock finishes below its 65% downside threshold, in which case investors will lose 1% for each 1% decline of the worse performing stock.

The notes are guaranteed by Morgan Stanley.

Morgan Stanley & Co. LLC is the underwriter.

Issuer:Morgan Stanley Finance LLC
Guarantor:Morgan Stanley
Issue:Contingent income autocallable securities
Underlying stock:Celgene Corp. (Symbol: CELG) and Amgen Inc. (Symbol: AMGN)
Amount:$1,143,000
Maturity:Oct. 29, 2020
Coupon:8.28% per year, payable quarterly if each stock closes at or above downside threshold level on determination date for that quarter
Price:Par
Payout at maturity:If each stock finishes at or above downside threshold, par plus contingent coupon; otherwise, 1% loss per 1% decline of worse performing stock
Call:At par plus contingent coupon if stock closes at or above initial level on any quarterly determination date beginning April 27, 2018
Initial share price:$120.34 for Celgene, $180.37 for Amgen
Downside threshold:$78.221 for Celgene, $117.241 for Amgen; 65% of initial share price
Pricing date:Oct. 24
Settlement date:Oct. 27
Agent:Morgan Stanley & Co. LLC
Fees:2.5%
Cusip:61768CSA6

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.